Halozyme Therapeutics (NASDAQ:HALO) Releases FY 2025 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 4.950-5.350 for the period, compared to the consensus estimate of 4.690. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Halozyme Therapeutics also updated its FY 2024 guidance to 4.000-4.200 EPS.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $51.19 on Wednesday. The firm has a market cap of $6.51 billion, a price-to-earnings ratio of 16.95, a PEG ratio of 0.44 and a beta of 1.24. The business’s 50 day moving average is $50.10 and its two-hundred day moving average is $54.00. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics has a 52-week low of $33.15 and a 52-week high of $65.53.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on HALO. JMP Securities upped their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. JPMorgan Chase & Co. downgraded Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and boosted their price target for the company from $52.00 to $57.00 in a report on Thursday, September 19th. Piper Sandler raised their price objective on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a research note on Monday, November 4th. Finally, HC Wainwright reiterated a “buy” rating and set a $68.00 target price on shares of Halozyme Therapeutics in a research note on Monday, December 30th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $61.11.

Insider Transactions at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the transaction, the director now directly owns 43,611 shares in the company, valued at approximately $2,180,986.11. This trade represents a 18.65 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.70% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.